



PATENT  
ATTORNEY DOCKET NO. 50111/043002

Certificate of Mailing: Date of Deposit: October 22, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Guy E. Beardsley  
Printed name of person mailing correspondence

*Guy E. Beardsley*  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Stinson et al.	Art Unit:	1645
Serial No.:	09/215,163	Examiner:	J. Graser
Filed:	December 18, 1998	Customer No.:	21559
Title:	HUMANIZED MONOCLONAL ANTIBODIES THAT PROTECT AGAINST SHIGA TOXIN INDUCED DISEASE		

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action following the filing of a Request for Continued Examination under 37 C.F.R. § 1.114.


If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date:

22 October 2004

  
James D. DeCamp, Ph.D.  
Reg. No. 43,580

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

Attorney Docket No.

50111/043002

Serial No.

09/215,163

Applicant

Stinson et al.

Filing Date

December 18, 1998

Group

1645

IDS Filed

October 22, 2004

Customer No.

21559

## U.S. PATENTS OR PATENT APPLICATIONS

Examiner's Initials	Patent or Publication Number	Publication or Issue Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	2002/0160005	10/31/2002	Tzipori et al.			
	2003/0082189	5/1/2003	Tzipori et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 98/20903 ✓	5/22/1998	W.I.P.O.			
	WO 99/45962 ✓	9/16/1999	W.I.P.O.			
	WO 99/59629 ✓	11/25/1999	W.I.P.O.			

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Downes et al., "Affinity Purification and Characterization of Shiga-Like Toxin II and Production of Toxin-Specific Monoclonal Antibodies," <i>Infection and Immunity</i> 56:1926-1933 (1988). ✓
	Edwards et al., "Humanization of Monoclonal Antibodies Against <i>Escherichia Coli</i> Toxins STX1 and STX2," V110/V11:113, Abstract (1997) ✓
	Jackson et al., "Functional Analysis of the Shiga Toxin and Shiga-Like Toxin Type II Variant Binding Subunits by Using Site-Directed Mutagenesis," <i>Journal of Bacteriology</i> 172:653-658 (1990). ✓
	Kelley, R., "Engineering Therapeutic Antibodies," In Protein Engineering: Principles and Practice. Ed. Cleland J.L. and Craik C.S., Chapter 15:399-434, Wiley-Liss Inc. (1996). ✓
	O'Brien et al., "Immunochemical and Cytotoxic Activities of <i>Shigella dysenteriae</i> 1 (Shiga) and Shiga-Like Toxins," <i>Infection and Immunity</i> 35:1151-1154 (1982).
	Paton et al., "Pathogenesis and Diagnosis of Shiga Toxin-Producing <i>Escherichia Coli</i> Infections," <i>Clinical Microbiology Reviews</i> , 11:450-479 (1998). ✓
	Perera et al., "Isolation and Characterization of Monoclonal Antibodies to Shiga-Like Toxin II of Enterohemorrhagic <i>Escherichia coli</i> and Use of the Monoclonal Antibodies in a Colony Enzyme-Linked Immunosorbent Assay," <i>Journal of Clinical Microbiology</i> , 26:2127-2131 (1988). ✓

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50111/043002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))				Serial No.	09/215,163
				Applicant	Stinson et al.
				Filing Date	December 18, 1998
				Group	1645
				IDS Filed	October 22, 2004
				Customer No.	21559
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
	Schmitt et al., "Two Copies of Shiga-Like Toxin II-Related Genes Common In Enterohemorrhagic <i>Escherichia coli</i> Strains Are Responsible for the Antigenic Heterogeneity of the O157:H <sup>-</sup> Strain E32511," <i>Infection and Immunity</i> , 59:1065-1073 (1991). ✓				
	Strockbine et al., "Characterization of Monoclonal Antibodies against Shiga-Like Toxin from <i>Escherichia coli</i> ," <i>Infection and Immunity</i> , 50:695-700 (1985). ✓				
	Tesh et al., "Comparison of the Relative Toxicities of Shiga-Like Toxins Type I and Type II for Mice," <i>Infection and Immunity</i> , 61:3392-3402 (1993). ✓				
EXAMINER			DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					